The incidence of lung cancer in Northern Ireland: 1991–1992

A comparative study

Pauline Wilkinson1 · Joe MacMahon2 · Gilbert MacKenzie3

Received: 16 July 2021 / Accepted: 8 September 2021 / Published online: 16 October 2021 © The Author(s) 2021

Abstract

Introduction Lung cancer is the leading cause of cancer deaths in many Western countries, but its incidence has never been studied in Northern Ireland.

Aims Accordingly, the present study was mounted to determine, for the first time, the incidence of the condition in Northern Ireland and to compare the findings with other regions in the British Isles.

Methods A notification study of the incidence of lung cancer (ICD 162) was conducted in Northern Ireland during 1991/1992. Notifications from 6 sources were computerised and linked. Incident cases were identified and analysed in relation to Age, Sex and Geographical region—Northern Ireland, England and Wales, Scotland and the Republic of Ireland.

Results Some 900 incident cases of lung cancer were identified. The incidence rate per 100,000 population was found to be 57.04. Mortality underestimated incidence by 12.5%. (p < 0.05). The male to female incidence ratio was 2.1:1, and this ratio was similar in other regions, except Scotland, where the ratio was 1.7:1. The null hypothesis of a common incidence distribution across regions was formally rejected. A variety of models were fitted and a model in which the log-odds on incidence was a quadratic function of age fitted most of the regional data.

Conclusions Northern Ireland had the lowest incidence of lung cancer in the UK, but its overall rate was still 40% higher than that observed in the Republic of Ireland which had the lowest rate in the British Isles. Across regions, the pattern of incidence by age and sex was complicated, but a linear logistic model fitted all of the Irish data and the female data in Scotland, satisfactorily.

Keywords Cancer registration · Incidence · Lung cancer · Regional comparisons · Statistical modelling

Introduction

Lung cancer is the leading cause of cancer deaths in many Western countries. It has become the major cause of cancer deaths in males and is only superseded by breast cancer in women. Even this pattern has altered in some countries with lung cancer overtaking breast cancer as the leading cause of cancer deaths in women, for example in Scotland [1, 2].

Differences in the incidence of lung cancer have been reported throughout the world: Scotland, the USA and New Zealand (Maoris) having high rates and India, Israel, Singapore and Thailand having low rates [3–6]. Of particular note is the rapidly increasing incidence within developing and Eastern European countries. As with mortality, differences in incidence have been reported between the sexes—particularly the changing rates among women [7–9]. Such geographical and sex differences may be accounted for, in...
part, by differing patterns of smoking and tobacco consumption [10–14].

In Northern Ireland, population data pertaining to the incidence of lung cancer have not previously been published. When the study was started (1991), only three papers had dealt with the characteristics of the disease in Northern Ireland [15–17] and, of these, two had focused on mortality [15, 16], while the third [17] dealt with survival in a surgical setting. The lack of interest in incidence, per se, is rather surprising, but, may be attributable to the absence of cancer registration facilities in the Province. A properly constituted population-based cancer registration system1 was only established in 1994 [18]. Prior to that date, the notification system in use was estimated to be approximately 60% complete in relation to lung cancer registration [19]. The absence of accurate incidence data hampers national and international comparisons and limits planning.

As in other regions of the UK, mortality data are routinely available from the annual reports of the Registrar General (NI). The usefulness of such data is, of course, limited [20–23] and any orthodox approach to the monitoring and control of lung cancer requires a detailed knowledge of the incidence distribution. Accordingly, a comprehensive epidemiological study was set up to measure, inter alia, the incidence of lung cancer in Northern Ireland during 1991/1992 and to compare the findings with other regions of the British Isles.

Methods

These have been described in greater detail elsewhere [24]. Briefly:

Diagnosis of lung cancer

Diagnosis was based upon existing histological, radiological and clinical evidence which was considered by one of us (PW). Where histological or cytological evidence was lacking, the diagnosis was made by PW based upon available investigations and the clinical course of the illness. In this way, only cases of primary lung cancer (ICD 162, 9th revision) were included in the study.

Definition of incidence

An incident case was defined to be a person of any age resident within Northern Ireland who was newly diagnosed as having primary lung cancer (ICD 162, 9th revision) during the one year period 1/10/1991 to 30/9/1992. For example, as framed, the definition specifically excludes cases of mesothelioma (ICD 163) or secondary lung cancer.

Sources of ascertainment

Incident cases were identified during the study period using a multi-source notification scheme. Notification sources included: general practitioners, hospital physicians and surgeons, radiotherapists, pathology laboratories, the office of the Registrar General (NI) and the NI Cancer Notification Scheme.

A simple notification form was designed and circulated to hospital and community-based Physicians and Surgeons at regular intervals together with reminding letters. These forms were completed by the notifying Physicians or Surgeons and returned to the researcher. In addition the thoracic Surgeons provided copies of discharge letters for in-patient, out-patient procedures and admissions. Separate arrangements were made with the Radiotherapy department, Pathology laboratories, Registrar General’s Office and the NI Cancer Notification Scheme enabling them to notify cases routinely. Furthermore, PW regularly monitored the notifying agencies and inspected log-books, computerised listings and other records in individual hospitals and units to ensure that cases had not been inadvertently overlooked.

Multi-source notifications and incidence

Notifications from individual agencies were computerised in the Department of Epidemiology and Public Health, The Queen’s University of Belfast, and linked using the patient’s name, sex and date of birth. A file of potentially incident cases of lung cancer was produced and up-dated regularly throughout the study period. Following notification, PW reviewed the hospital notes and general practitioner notes (if necessary). For example, even when a notification was based on a single source (e.g., death certificate data) the patient’s hospital notes were retrieved (via a master patient index) to determine whether the case fulfilled the study criteria, and, if so, to abstract other pertinent clinical data. This method was applied for all cases regardless of whether they were notified from single or multiple sources. In this way, the number of incident cases of primary lung cancer occurring in Northern Ireland during the study period, and the pattern of notification among the different sources, was ascertained and verified.

1 The Ulster Cancer Foundation, and the Department of Epidemiology and Public Health, Queen’s University of Belfast, actively encouraged the establishment of the NI Cancer Registry bringing the late Dr. Calum Muir, then Deputy Director of WHO, to Belfast as a distinguished international advisor.
Comparative data

Population and mortality data for lung cancer (ICD 162) were obtained from the Registrars General of Northern Ireland [25, 26] (1991/1992) and Scotland (1991/1992), respectively. For Scotland, incidence data were obtained from the Scottish Cancer Registry, whereas the Office of National Statistics provided incidence and mortality data for England and Wales as did the National Cancer Registry in the Republic of Ireland (personal communications). In general, the data selected for comparison were the latest (population and matching incidence) available at the time of writing.

Statistical methods

Standard statistical methods appropriate to the analysis of incidence rates were employed. In particular comparisons, it was found convenient to model the probability of incidence, \( \theta \), by the linear logistic function [27], whence the natural logarithm of the ‘odds’ on incidence is given by:

\[
\log \theta/(1 - \theta) = \alpha + \beta \text{(Age)} + \gamma \text{(Sex)} + \delta \text{(Region)}
\]  

(1)

where \( \alpha \), \( \beta \), \( \gamma \) and \( \delta \) are unknown parameters describing dependence on the three factors studied. The generalised linear interactive modelling package, GLIM [28], was used to fit various forms of model (1) to the incidence data considered later.

In addition, age-standardised rates were calculated using the direct method. The 5% level of statistical significance, which should be regarded as a nominal reporting level, was used in tests of statistical hypotheses and in the construction of confidence intervals (CIs).

Results

Ascertainment

During the study period 3814 notification forms were received relating to 1818 individual possibly incident cases of lung cancer. However, of these 1818, the following were excluded: 283 (15.6%) with the wrong diagnosis (for example, no proven malignancy, secondary lung cancer, lymphoma), 605 (33.3%) with a diagnosis outside the study period, 12 (0.7%) who were resident outside Northern Ireland and 18 (1.0%) who could not be traced. In all, 918 (50.5%) cases were excluded leaving 900 incident cases of primary lung cancer for analysis.

Overall, a total of 2739 notifications were received for these 900 incident cases (a ratio of 3:1). Table 1, which groups the sources into 4 major categories S01–S04, illustrates the value of the multi-source notification approach adopted in the study. For example, a single source study based on the NI Cancer Notification System (S04) would
have identified only 361 cases, 40.1% of the true incidence, compared with a maximal 676 cases, 75.1%, using only GPs, hospital physicians and other specialists (SO1). No single source studied was sufficiently complete to have been used for serious epidemiological purposes. Moreover, a study employing 3 sources (SO1 and SO2 and SO4) but ignoring death certification data (SO3) would have missed 115 cases, 12.8% of the true incidence. Remarkably, only 137 cases (15.2%) were known to all 4 sources during the course of the study.

NI incidence

Of the 900 incident cases, 601 were male and 299 were female. The 1991 census for Northern Ireland enumerated the population as 1,577,834 persons (769,057 males and 808,777 females). Based on these figures, the incidence of lung cancer in Northern Ireland during the study year was 57.04 cases per 100,000 population (95% CI = 53.24, 60.84). The corresponding rates for males and females were 78.15 per 100,000 (95% CI = 71.78, 84.52) and 36.97 (95% CI = 32.69, 41.25), respectively. Overall, the male to female incidence ratio was 2.1:1.

Since mortality has been used consistently as a surrogate measure of incidence in Northern Ireland, it is interesting to quantify, for first time, the resulting bias. In 1991, 788 deaths from lung cancer (ICD 162) were reported in Northern Ireland, yielding a mortality rate of 49.94 per 100,000 population. This figure under-estimates the true incidence rate by 12.45% and is computed as 100 \( \times \frac{57.04 - 49.94}{57.04} \).

Since the mortality rate falls outside the 95% CI for the true incidence rate, we conclude that the incidence of lung cancer in NI is statistically significantly higher than the mortality. The 1991 sex-specific mortality rates were 73.60 and 27.44 for males and females and these figures underestimate the corresponding incidence rates by 5.82% and 25.78%, respectively. The underestimate for females is rather dramatic and highly statistically significant. A comparison with the mortality rates in 1992 reveals a similar pattern: the overall mortality rate under-estimates the true incidence rate by 16.02%; for males the underestimate is 16.68% and for females the underestimate is 14.93%. All of the mortality rates lie outside the 95% CIs for the corresponding true incidence rates.

Table 2 (a) shows the observed incidence rates (per 100,000) for Northern Ireland by age (20+ years), sex and persons the 75–79 year group the rate increased once more before declining in the 85+ years age group. While women reached their peak incidence at 70–74 years (210.53 per 100,000), men did not reach theirs until 80–84 years (694.12 per 100,000). The male to female incidence ratio rose steadily in each decade of age from a minimum of 0 in those aged 20–29 years through each decade—0.5, 1.9, 2.3, 2.5, and 2.9, respectively—to a maximum of 4.1 in those aged 80+ years (Table 2).

Regional comparisons

(a) Overall Incidence

Table 3 shows comparative incidence data (all ages and by sex) for the four major regions of the British Isles: Northern Ireland, England and Wales, Scotland and the Republic of Ireland. The data presented for the UK are the latest years available (at the time of writing) and 1994 is the first year for which incidence data were available on a national basis in the Republic of Ireland.

In the years studied, Northern Ireland had the lowest incidence of lung cancer within the UK. The highest rates were observed in Scotland where, remarkably, the crude rate was 1.7 times that observed in Northern Ireland, 1.4 times that observed in England and Wales and 2.4 times that seen in the Republic of Ireland. Among women the disparities were marginally greater: the crude incidence rate among Scottish women at 70.3 (per 100,000) was 2.7 times that of women in the Republic of Ireland. Allowing for age did not change the regional ranking but had the effect of reducing the differences between the regions, especially between Northern Ireland and England and Wales where the age-adjusted person rates were 38.3 and 39.0, respectively. The low age-standardised rates obtained in Table 3 result from
Table 2  Regional incidence rates for lung cancer (per 100,000 population) by age and sex

| Region | Males | | | | | | Females | | | | |
|--------|-------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|        | No. | Pop. | Rate | No. | Pop. | Rate | | | | | | | | | |
| NI     |     |      |      |     |      |      | | | | | | | | | | |
| 20-    | 0   | 124,358 | 0.0 | 1   | 123,984 | 0.8 | | | | | | | | | | |
| 30-    | 1   | 105,543 | 1.0 | 2   | 107,230 | 1.9 | | | | | | | | | | |
| 40-    | 19  | 93,128 | 20.4 | 10  | 94,699 | 10.6 | | | | | | | | | | |
| 50-    | 63  | 71,740 | 87.8 | 20  | 75,195 | 38.2 | | | | | | | | | | |
| 60-    | 228 | 61,212 | 372.5 | 106 | 73,207 | 145.1 | | | | | | | | | | |
| 70-    | 208 | 37,655 | 552.4 | 104 | 54,762 | 189.9 | | | | | | | | | | |
| 80+    | 82  | 12,394 | 661.6 | 47  | 29,294 | 160.4 | | | | | | | | | | |
| Total  | 601 | 506,030 | 118.8 | 299 | 558,951 | 53.5 | | | | | | | | | | |
| E and W |     |      |      |     |      |      | | | | | | | | | | |
| 20-    | 12  | 4178.9 | 0.3 | 5   | 4024.1 | 0.1 | | | | | | | | | | |
| 30-    | 90  | 3587.8 | 2.5 | 50  | 3532.1 | 1.4 | | | | | | | | | | |
| 40-    | 678 | 3416.7 | 19.8 | 397 | 3403.7 | 11.6 | | | | | | | | | | |
| 50-    | 2602 | 2636.0 | 98.7 | 1172 | 2648.7 | 44.3 | | | | | | | | | | |
| 60-    | 7924 | 2382.7 | 332.6 | 3770 | 2645.9 | 142.5 | | | | | | | | | | |
| 70-    | 9146 | 1531.3 | 597.3 | 4153 | 2167.4 | 191.6 | | | | | | | | | | |
| 80+    | 4297 | 576.6 | 745.2 | 2204 | 1376.0 | 160.2 | | | | | | | | | | |
| Total  | 24,749 | 18,318.9 | 135.1 | 11,751 | 19,797.7 | 59.4 | | | | | | | | | | |
| Scotland |     |      |      |     |      |      | | | | | | | | | | |
| 20-    | 2   | 417,522 | 0.5 | 0   | 406,000 | 0.0 | | | | | | | | | | |
| 30-    | 4   | 373,738 | 1.1 | 5   | 373,394 | 1.3 | | | | | | | | | | |
| 40-    | 97  | 329,420 | 29.4 | 66  | 334,196 | 19.7 | | | | | | | | | | |
| 50-    | 346 | 266,357 | 129.9 | 226 | 284,591 | 79.4 | | | | | | | | | | |
| 60-    | 1115 | 233,291 | 477.9 | 608 | 273,467 | 222.3 | | | | | | | | | | |
| 70-    | 1075 | 141,370 | 760.4 | 642 | 212,490 | 302.1 | | | | | | | | | | |
| 80+    | 471  | 50,148 | 939.2 | 306 | 125,062 | 244.7 | | | | | | | | | | |
| Total  | 3,110 | 1,811,846 | 171.7 | 1853 | 2,009,200 | 92.2 | | | | | | | | | | |
| ROI    |     |      |      |     |      |      | | | | | | | | | | |
| 20-    | 1   | 279,211 | 0.4 | 2   | 271,451 | 0.7 | | | | | | | | | | |
| 30-    | 6   | 242,158 | 2.5 | 2   | 249,877 | 0.8 | | | | | | | | | | |
| 40-    | 26  | 224,107 | 11.7 | 21  | 221,346 | 9.5 | | | | | | | | | | |
| 50-    | 146 | 159,950 | 91.3 | 52  | 156,035 | 33.3 | | | | | | | | | | |
| 60-    | 318 | 124,861 | 254.7 | 128 | 134,718 | 95.0 | | | | | | | | | | |
| 70-    | 380 | 85,082 | 446.6 | 198 | 111,355 | 177.8 | | | | | | | | | | |
| 80+    | 109 | 28,091 | 388.0 | 65  | 49,212 | 132.1 | | | | | | | | | | |
| Total  | 986 | 1,143,460 | 86.2 | 468 | 1,193,994 | 39.2 | | | | | | | | | | |

NB: Populations studied for ages 20+ years: NI = 1991/2, E and W = 1991, Scotland = 1992, and ROI = 1994

Table 3  Summary of crude and adjusted* regional incidence rates per 100,000 population

| Region | Males | | | | | | Females | | | | |
|--------|-------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|        | Crude | Adjusted | Crude | Adjusted | Crude | Adjusted |          |          |          |          |          |          |          |          |          | |
| NI     | 78.2  | 59.7 | 37.0 | 22.5 | 57.0  | 38.3 | | | | | | | | | |
| E and W | 99.0  | 60.2 | 45.0 | 22.9 | 71.4  | 39.0 | | | | | | | | | |
| Scotland | 125.8 | 81.0 | 70.3 | 36.8 | 97.1  | 55.3 | | | | | | | | | |
| ROI    | 55.7  | 45.1 | 26.1 | 17.7 | 40.8  | 30.4 | | | | | | | | | |

NB: Population years studied as Table 2, but for all ages. *World Population 1989
the structure of the (younger) World reference population chosen to facilitate International comparisons. Overall, both comparisons indicated that the rates in the Republic of Ireland were the lowest in the British Isles. However, it should be noted that the pattern of incidence in the Republic differed fundamentally from that observed in the other regions as the incidence rate of 40.8 (per 100,000) was lower than the corresponding mortality rate of 43.3. Such a finding may be due, at least in part, to under-ascertainment.

(b) Model Fitting

In order to compare the incidence of lung cancer in the four regions more formally, we adopted the model fitting approach described above. Using a linear logistic model we analysed the incidence in relation to three factors: Age, Sex and Region. A number of different linear logistic models were fitted to the regional data.

The null hypothesis of a common relationship between Incidence, Age and Sex in all four regions was tested. The regional homogeneity hypothesis was found to be untenable ($\chi^2 = 850.4$, df = 50, $p < 0.01$). This result suggests that the pattern of incidence by age and sex is rather complicated and that it may be more appropriate to fit models separately for males and females and for each region. Accordingly, the simple model:

$$\log_e \left[ \frac{\theta}{1 - \theta} \right] = \beta_0 + \beta_1 (\text{Age}) + \beta_2 (\text{Age}^2)$$

in which the logarithm of the odds on incidence is a quadratic function of age was used.

Table 4 summarises the results obtained. The quadratic model provided an adequate description of the incidence observed amongst: (a) Northern Irish males and females, (b) Scottish females and (c) Southern Irish males. Formally, it narrowly failed to describe the trend in age incidence in Southern Irish females ($\chi^2 = 10.4$, df = 4, $p < 0.05$, but almost all of the contribution to $\chi^2$ arose in one cell (20–29 yrs) in which 2 cases were observed, but only 0.27 were expected on the basis of the model. Ignoring this cell, the model also provides a satisfactory fit to the female data in the Republic.

The regression coefficients in Table 4 are all well identified statistically and their quantitative similarity is worth noting, particularly in relation to the lung cancer incidence data on the island of Ireland as a whole. Despite this, the model based on Eq. (2) did not explain the pattern of age-sex specific incidence observed in England and Wales nor among Scottish males. The observed and expected numbers of incident cases of lung cancer are shown in Table 5 for all 4 regions.

It will be noted that among males in England and Wales and in Scotland the model consistently and significantly: (a) over-estimated the incidence among those aged 50–59 years, (b) under-estimated the incidence in the next decade and (c) over-estimated the incidence among men aged 70–79 yrs. This pattern of lack of fit is also evident to a lesser (non-significant) extent in the incidence data for Northern Ireland, but is completely absent from the data observed in the Republic of Ireland. For females in England and Wales the model again failed to fit the observed numbers of incident cases aged 50–69 years (Table 5). However, the pattern of lack of fit differed somewhat from the male data observed in E and W.

Discussion

The data analysed above are now some 30 years old and this must be borne in mind when interpreting the findings above and the discussion which follows. Looking back, our main concern was that the absence of standard cancer registration facilities in Northern Ireland was limiting information about the true extent of lung cancer in the community. This deficiency had long concerned physicians, surgeons and epidemiologists alike. Accordingly, the study was undertaken to ascertain, for the first time, the incidence of lung cancer in Northern Ireland.
Method

From the outset methodological considerations were paramount and a comprehensive multi-source notification design was adopted in order to maximise the ascertainment of cases of lung cancer. The procedures implemented in this study were even more comprehensive—especially with respect to the number of sources polled and the amount of pro-active searching—than those currently being followed by the recently established NI Cancer Registry. Accordingly, very few cases, if any, were thought to have been missed.

The findings, that no single source was sufficiently complete and that only 137 of the 900 incident cases were known to all 4 sources during the course of the study constitute a rather remarkable indictment of the reporting systems which existed in Northern Ireland during 1991/1992. Thus, Table 1 should prove a valuable aid to the workings of the new registry. However, it is unlikely that the method of notification of cancer of the lung is peculiarly unique and the need for the NI Registry to pro-actively pursue a comprehensive (multi-source) notification strategy was clear.

The number of incident cases, at 900, exceeded the mortality by 112 cases. As noted earlier mortality had been used consistently by the DHSS and other health planners as a surrogate measure for incidence in the Province. The results show that this particular strategy under-estimated the true extent of the disease in the community by 12.45%. In the absence of temporal incidence data it was impossible to estimate the duration of such under-estimation, but the implications for funding and resource allocation in the Province would not be lost on specialists in the field.

Local comparisons

Although, in the years studied, Northern Ireland had the lowest incidence of lung cancer in UK the overall rate was still 40% higher than the rate in the Republic of Ireland which, on these data, had the lowest rate in the British Isles. The absence of national incidence data in the Republic for 1991–1992 hampers the interpretation of the comparison. As we remarked earlier, the data for 1994 were the first to become available on a national basis in the Republic and some allowance must be made for potential under-ascertainment in the early years of the development of a new registry. Even so, it is highly unlikely that any such allowance would alter the Republic’s ranking in the regional comparison.

The null hypothesis of regional homogeneity in the age-sex incidence distribution was rejected. Despite this, we have demonstrated that a simple sex specific model in which the logarithm of the odds on incidence is a quadratic function of age fitted the Northern Ireland and Republic of Ireland data adequately. This model also explained the age-specific incidence distribution among Scottish females. However, it did not fit the data for England and Wales nor for Scottish males: i.e., the log-odds on incidence does not follow a simple quadratic form in age. It may be, of course, that a more general model would apply in each region and we recognise that factors such as smoking status, exposure to passive smoke, and socio-economic status have not been taken into account in this paper.

| Region/Age | Males | Females |
|------------|-------|---------|
|            | Observed | Expected | Observed | Expected |
| NI         |         |         |         |         |
| 20-        | 0       | 0.10    | 1       | 1.13     |
| 30-        | 1       | 1.68    | 2       | 1.50     |
| 40-        | 19      | 16.04   | 10      | 10.44    |
| 50-        | 63      | 73.56   | 29      | 37.89    |
| 60-        | 228     | 205.73  | 106     | 94.71    |
| 70-        | 208     | 228.68  | 104     | 105.82   |
| 80+        | 82      | 75.20   | 47      | 48.49    |
| E and W    |         |         |         |         |
| 20-        | 12      | 8.76    | 5       | 3.19     |
| 30-        | 90      | 63.35   | 50      | 43.60    |
| 40-        | 678     | 717.64  | 397     | 362.24   |
| 50-        | 2602    | 2733.92 | 1172    | 1345.21  |
| 60-        | 7924    | 7605.58 | 3770    | 3529.96  |
| 70-        | 9146    | 9381.24 | 4153    | 4255.29  |
| 80+        | 4297    | 4238.51 | 2204    | 2191.50  |
| Scotland   |         |         |         |         |
| 20-        | 2       | 0.78    | 0       | 0.50     |
| 30-        | 4       | 10.72   | 5       | 7.36     |
| 40-        | 97      | 86.70   | 66      | 57.96    |
| 50-        | 346     | 376.60  | 226     | 236.56   |
| 60-        | 1115    | 1036.36 | 608     | 593.53   |
| 70-        | 1075    | 1155.53 | 642     | 656.65   |
| 80+        | 471     | 443.34  | 306     | 300.44   |
| ROI        |         |         |         |         |
| 20-        | 1       | 0.23    | 2       | 0.27     |
| 30-        | 6       | 3.72    | 2       | 2.97     |
| 40-        | 26      | 34.73   | 21      | 19.11    |
| 50-        | 146     | 137.31  | 52      | 59.01    |
| 60-        | 318     | 325.95  | 128     | 134.51   |
| 70-        | 380     | 371.23  | 198     | 176.99   |
| 80+        | 109     | 112.82  | 65      | 75.13    |

Observed and expected numbers based on the logistic model in age and age-squared by age, sex and region

NB:
1. Population years as in Table 3
2. Standardized residual, $z = (\text{obs} - \text{exp})/\sqrt{\text{exp}}$ and $z^2 \approx \chi^2$ with df=1

Table 5 Regional comparison

| Region/Age | Males | Females |
|------------|-------|---------|
|            | Observed | Expected | Observed | Expected |
| NI         |         |         |         |         |
| 20-        | 0       | 0.10    | 1       | 1.13     |
| 30-        | 1       | 1.68    | 2       | 1.50     |
| 40-        | 19      | 16.04   | 10      | 10.44    |
| 50-        | 63      | 73.56   | 29      | 37.89    |
| 60-        | 228     | 205.73  | 106     | 94.71    |
| 70-        | 208     | 228.68  | 104     | 105.82   |
| 80+        | 82      | 75.20   | 47      | 48.49    |
| E and W    |         |         |         |         |
| 20-        | 12      | 8.76    | 5       | 3.19     |
| 30-        | 90      | 63.35   | 50      | 43.60    |
| 40-        | 678     | 717.64  | 397     | 362.24   |
| 50-        | 2602    | 2733.92 | 1172    | 1345.21  |
| 60-        | 7924    | 7605.58 | 3770    | 3529.96  |
| 70-        | 9146    | 9381.24 | 4153    | 4255.29  |
| 80+        | 4297    | 4238.51 | 2204    | 2191.50  |
| Scotland   |         |         |         |         |
| 20-        | 2       | 0.78    | 0       | 0.50     |
| 30-        | 4       | 10.72   | 5       | 7.36     |
| 40-        | 97      | 86.70   | 66      | 57.96    |
| 50-        | 346     | 376.60  | 226     | 236.56   |
| 60-        | 1115    | 1036.36 | 608     | 593.53   |
| 70-        | 1075    | 1155.53 | 642     | 656.65   |
| 80+        | 471     | 443.34  | 306     | 300.44   |
| ROI        |         |         |         |         |
| 20-        | 1       | 0.23    | 2       | 0.27     |
| 30-        | 6       | 3.72    | 2       | 2.97     |
| 40-        | 26      | 34.73   | 21      | 19.11    |
| 50-        | 146     | 137.31  | 52      | 59.01    |
| 60-        | 318     | 325.95  | 128     | 134.51   |
| 70-        | 380     | 371.23  | 198     | 176.99   |
| 80+        | 109     | 112.82  | 65      | 75.13    |

2009

Irish Journal of Medical Science (1971-) (2022) 191:2003–2012

© Springer
International comparisons

On a world-wide scale, the 1991–1992 Northern Ireland incidence rate of 57.0 per 100,000 population was intermediate, being lower than some countries—England and Wales, Scotland, USA, and Canada—but, higher than others—Australia, India, Israel and Thailand [5–8]. Neither was the male to female incidence ratio of 2.1 to 1 particularly unusual. Data from the International Agency for Research on Cancer [3] showed marked inter-country variation in male to female incidence ratios, ranging from less than 3:1 (USA, Denmark and Israel) to those in excess of 9:1 (Germany, France and Italy). Accordingly, it seems that individuals in Northern Ireland were not at particularly high risk of developing the disease in 1991/92.

Postscript

In 2021, the epidemiological picture is rather different and the purpose of this new section is simply to bring the regional incidence results up to date.

Examining current Registry data [29–33], we were able to compile Fig. 2 which shows the regional trends in crude incidence rates for the period 1993–2018. Not all Registries have data available for the whole period: for example, the Welsh Registry has only published data from 2002.

The pattern which emerges is hardly re-assuring, all of the trends are increasing. The figure does, however, largely confirm the 1991–1992 ranking (highest–lowest) of Scotland, England, Northern Ireland and the Republic and confirms the conclusion that the position of ROI would remain unchanged, when its registry was fully operational.

It may be argued that the increasing trends are due to aging populations. Whilst this may be true in part, it seems an unlikely explanation for the trend in NI, where there was a shallow decline after 1991–1992 until c2000. Thereafter, a gradual increasing trend was experienced until 2010, when the increase accelerated up to the higher rates observed in 2016–2018. The 2017 rate in NI is c72, an increase of 26.3% over the 1991–1992 rate (57.0, Table 3) and it has been driven by a dramatic rise in incidence among females (not shown). The most striking finding is that the incidence rate in NI exceeded the rate in England in 2016! In 1991–1992 epidemiologists would not have thought such a result possible.

These increases in NI and elsewhere are the more puzzling, when considered against a backcloth of successful smoking bans in public places and declining population smoking prevalence rates in the UK, down from 20.2% in 2011 to 14.1% in 2019, [34], overall, and in the Republic, down from 28.3% in 2008 (last high) to 15.0% in 2020 (HSE, 2020) [35].

Thus, it seems that the conclusion reached about NI’s position in 1991–1992 was rather optimistic and further studies are now required to identify the factors underpinning these increasing trends.

Acknowledgements

The authors gratefully acknowledge the assistance of the Registrar General of Northern Ireland, the staff of the Office of National Statistics, the staff of the Scottish Cancer Registry, Dr. Harry Comber, Director of the National Cancer Registry in the Republic of Ireland and all of those who co-operated with the original study. We would also like to thank Miss Kay Andrews, The Department of Epidemiology and Public Health, The Queen’s University of Belfast, for her careful preparation and computerisation of the data collected in the course of the Northern Ireland study. The staffs of the Registries in Northern Ireland, Scotland, England, Wales and in the Republic of Ireland were particularly helpful in providing the more recent data plotted in Fig. 2. The English data were provided by the National Cancer Registration and Analysis Service (NCRAS). Finally we would like to thank a referee for valuable comments which improved the paper.

Authors’ contributions

The study was initiated by Dr. JM. The paper was drafted by the first and third authors. Subsequently, both of these authors worked to improve the draft. The first author wrote the Introduction and part of the Discussion while the third author wrote the statistical analysis and part of the discussion. All three authors were involved in interpreting the findings and refining the paper for publication. All authors read and approved the final manuscript.

Funding

Open Access funding provided by the IRel Consortium. This paper arose from Dr. Wilkinson’s MD carried out in the Department of Epidemiology and Public Health, Queen’s University Belfast. Dr. Wilkinson was supported, in part, by Research Funds from the Respiratory Unit’s Research Fund (Belfast City Hospital) and Action Cancer, Belfast.
Declarations

Ethics approval and consent for publication  This study was conducted in accordance with the ethical standards of the NHS Eastern Health and Social Services Board and within the 1964 Helsinki Declaration and its later amendments. The study was approved by the Research Ethical Committee of the Queen’s University of Belfast.

Competing interests  The authors have no competing interests.

Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Gillis CR, Hole DJ, Lamont DW, Graham AC, Ramage S (1992) The incidences of lung cancer and breast cancer in women in Glasgow. BMJ 305:1331
2. Matthews P (1993) Lung cancer and breast cancer in women (letter). BMJ 306:144
3. Waterhouse J, Muir C, Shanmugaratnam K et al. (1992) Cancer incidence in five continents, vol VI. IARC, Lyon
4. Waterhouse J, Muir C, Shanmugaratnam K et al. (1982) Cancer incidence in five continents, vol 4. IARC, Lyon
5. Lee HP, Duffy SW, Day NE et al (1988) Recent trends in cancer incidence among Singapore Chinese. Int J Cancer 42:159–166
6. La Vecchia C, Franceschi S (1984) Italian lung cancer death rates in young males (letter). Lancet 1:406
7. Beamin JF, Stein A Jr, Andrews JL (1975) Changing epidemiology of lung cancer. Increasing incidence in women. Med Clin N Am 59(2):315–325
8. Beard CM, Annegers JF, Woolner LB, Kurland LT (1985) Bronchogenic carcinoma in Olmsted county 1935–79. Cancer 55:2026–2030
9. Devesa SS, Blot WJ, Fraumeni JF (1989) Declining lung cancer rates among young men and women in the United States: a cohort analysis. J Nat Cancer Inst 81:1568–1571
10. Doll R, Hill AB, Gray PG, Parr EA (1959) Lung cancer mortality and the length of cigarette ends. BMJ 1:322–325
11. Doll R, Hill AB (1952) A study of the aetiology of carcinoma of the lung. BMJ 2:1271–1286
12. Hammond EC (1958) Lung Cancer death rates in England and Wales compared to those in the USA. BMJ 2:649–654
13. Wynder EL, Bross IJ, Cornfield J et al (1956) Lung cancer in women. N Eng J Med 225(24):1111–1121
14. Wynder EL, Mabraith K, Beattie EJ (1970) The epidemiology of lung cancer. Recent Trends. JAMA 213(13):2221–2228
15. Dean G (1966) Lung cancer and bronchitis in Northern Ireland 1961–62. BMJ 1:1506–1514
16. Patterson CC, Kee F (1991) Geographical variations and recent trends in cancer mortality in Northern Ireland (1979–88). Ulster Med J 60(2):137–149
17. Smiley TB, Cheeseman EA (1956) Cancer of the lung in Northern Ireland. Ulster Med J 25:62–74
18. Gavin AT et al. (1995) Cancer deaths in Northern Ireland. An analysis of patterns and trends. Cancer Registry, Issue 1:3. Belfast Universities Press
19. Gavin A (1989) A handbook on cancer in Northern Ireland. Ulster Cancer Foundation, Belfast
20. Percy CL, Miller BA, Gloeckler Ries LA (1990) Effect of changes in cancer classification and the accuracy of death certification on trends in cancer mortality. Ann N Y Acad Sci 609:87–99
21. Alderson MR, Meade TW (1967) Accuracy of diagnosis on death certificates compared to that in Hospital Records. Br J Prevent Med 21:22–29
22. Medical Services Study Group of the Royal College of Physicians of London (1978) Death certification and epidemiological research. Br Med J 2:1063–1065
23. Moriyama IM (1989) Problems in measurement of accuracy of death statistics. Am J Pub Health 79(10):1349–50
24. Wilkinson P (1995) Lung cancer in Northern Ireland 1991–92. MD Thesis, The Queen’s University of Belfast 1:1–204
25. (1991) Annual report of the Registrar General for Northern Ireland. HMSO
26. (1992) Annual report of the Registrar General for Northern Ireland. HMSO
27. Cox DR (1970) Analysis of binary data. Methuen, London, p 87
28. Healy MJR (1988) GLIM an introduction. Clarendon, Oxford, p 83
29. NI Cancer Registry, Queen’s University Belfast. https://www.qub.ac.uk/research-centres/nicr/CancerInformation/official-statistics/BySite/LungTracheaBronchus/
30. Scottish Cancer Registry,Gyle Square, 1 South Gyle Crescent, Edinburgh EH12 9EB. https://www.isds.scotland.org/Health-Topics/Cancer/Publications/2019-04-30/visualisation.asp
31. National Cancer Registration and Analysis Service, Public Health England. Wellington House London, SE1 8UG Special data request to NCRA Enquiries@phe.gov.uk
32. Lung Cancer Incidence rates 2002–2018. Welsh Cancer Registry. 2 Capital Quarter, Tyndall Street, Cardiff CF10 4BZ. https://phw.nhs.wales/services-and-teams/welsh-cancer-intelligence-and-surveillance-unit-wcisu/
33. Long Cancer Incidence rates 1994–2017. National Cancer Registry of Ireland. Building 6800, Cork Airport Business Park, Kin sale Road, Cork, Ireland. https://www.ncri.ie/data/incidence-statis tics
34. Adult smoking Habits in the UK: 2019 (2019) Office of National Statistics. Government Buildings, Cardif f Road, Newport, South Wales, NP10 8XG. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifefeepecta nciesbulletins/adultsmokinghabitinsgreatbritain/2019thepropo rtion-who-are-current-smokers-in-the-uk-its-consistent-count ries-and-local-areas-2011-to-2019
35. The prevalence of smoking in Ireland. Health Service Executive (HSE) (2020) Tracker Survey 2020, slide 4, Figure 1. https://www.hse.ie/eng/about/who/tobaccocontrol/research/smoking-in-irelan d-2020.pdf

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Authors and Affiliations

Pauline Wilkinson¹ · Joe MacMahon² · Gilbert MacKenzie³

¹ King’s College Hospital, London, UK
² The Belfast City Hospital, Belfast, Northern Ireland, UK
³ Centre of Biostatistics, University of Limerick, Limerick, Ireland